OverviewSuggest Edit

PamGene is a company providing a 3D array platform to measure the activity of proteins, mainly kinases, phosphatases, and nuclear receptors. Its services include lead optimization, translational and preclinical research, and biomarker discovery. The company develops IOpener, a diagnostic blood test for the measurement of real-time cellular kinome activity.
HQ's-Hertogenbosch, NL

Latest Updates

Employees (est.) (Sept 2021)39(+3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at PamGene

John Groten

John Groten

Managing Director
Rinie van Beuningen

Rinie van Beuningen

Vice President Business Development
Martijn Dankers

Martijn Dankers

Vice President Sales & Customer Care
Show more

PamGene Office Locations

PamGene has offices in 's-Hertogenbosch and Stratford
's-Hertogenbosch, NL (HQ)
Wolvenhoek 10
Stratford, CT, US
1345 Barnum Ave Ste 9
Show all (2)

PamGene Financials and Metrics

Summary Metrics

Founding Date


PamGene total Funding

$20.3 m

PamGene latest funding size

$2.7 m

Time since last funding

17 years ago

PamGene investors

PamGene's latest funding round in March 2005 was reported to be $2.7 m. In total, PamGene has raised $20.3 m
Show all financial metrics

PamGene Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

PamGene Online and Social Media Presence

Embed Graph

PamGene Blogs

PamGene highlights new publications underscoring the importance of its kinome activity profiling technology, the basis of the IOpener® diagnostic test

Today, PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, highlights eight publications in international journals that have confirmed that kinase-activity profiling can aid disease understanding a…

PamGene, Novigenix and Radboud University Medical Center secure Eurostars funding to develop a multi-omic predictive immunotherapy response test for bladder cancer patients

PRECISE, a Dutch-Swiss consortium between PamGene International B.V., Novigenix SA and Radboud University Medical Center, has been awarded a Eurostars grant of up to €1 million to develop a novel in-vitro diagnostic liquid biopsy test for accurate prediction of response to immunotherapy in bladder c…

Learning why patients display poor response to a therapy by looking at deregulated kinase signaling

Kinases have been running like a thread through Dr. Julhash Uddin Kazi’s career. They also played the lead part in the Lund University’s Associate Professor of Molecular Medicine’s recent Nature Precision Oncology publication titled: The Aurora kinase/β-catenin axis contributes to dexamethasone resi…

PamGene receives extended ISO 13485:2016 certification for its IOpener® immunotherapy selection test services

PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, today announced it has received extension of its ISO 13485:2016 certification. The extension completes PamGene’s ISO-certificate and is an import…

PamGene shares experience on biomarker development and ICI therapy response prediction at Cancer Bioinformatics Symposium

The 1st Annual Cancer Bioinformatics Symposium at the University of Toledo College of Medicine and Life Sciences will take place February 5th. The full day, online event champions collaboration between basic science cancer researchers and bioinformaticians. An international panel of research scienti…

Journal for ImmunoTherapy of Cancer publication – Kinase activity profiling as a predictor of response to ICI treatment

Journal for ImmunoTherapy of Cancer published the results of a study focusing on the potential of kinase activity profiling to predict the response of Melanoma and Non Small Cell Lung Cancer (NSCLC) patients to Immune Checkpoint Inhibitor (ICI) therapy. Despite significant advances in cancer treatme…
Show more

PamGene Frequently Asked Questions

  • When was PamGene founded?

    PamGene was founded in 2000.

  • Who are PamGene key executives?

    PamGene's key executives are John Groten, Rinie van Beuningen and Martijn Dankers.

  • How many employees does PamGene have?

    PamGene has 39 employees.

  • Who are PamGene competitors?

    Competitors of PamGene include BIOFABICS, River BioMedics and Cellendes.

  • Where is PamGene headquarters?

    PamGene headquarters is located at Wolvenhoek 10, 's-Hertogenbosch.

  • Where are PamGene offices?

    PamGene has offices in 's-Hertogenbosch and Stratford.

  • How many offices does PamGene have?

    PamGene has 2 offices.